Justin Merszei, MD
Nephrology · Houston, TXNPI 1649252529
Payments from drug & device makers
Across 601 payments — averaging $639.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$192K
- Quanta Dialysis Technologies Inc$150K
- CSL Behring$22K
- Calliditas Therapeutics US Inc.$10K
- AstraZeneca$2K
- Amgen$1K
- plus $6K from 23 others
Across 3 payments — averaging $13,091 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$39K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 2 | $192,229 |
| Quanta Dialysis Technologies Inc | 138 | $150,093 |
| CSL Behring | 9 | $22,258 |
| Calliditas Therapeutics US Inc. | 9 | $9,746 |
| AstraZeneca | 30 | $2,451 |
| Amgen(2 entities) | 87 | $1,197 |
| Mallinckrodt Hospital Products Inc. | 44 | $1,065 |
| OPKO Pharmaceuticals, LLC | 82 | $768 |
| Inari Medical, Inc. | 7 | $579 |
| Diality Inc. | 2 | $496 |
| Vifor Pharma, Inc. | 48 | $482 |
| Bayer | 42 | $469 |
| Akebia Therapeutics Inc | 21 | $447 |
| Boehringer Ingelheim | 23 | $360 |
| Mallinckrodt Enterprises LLC | 5 | $274 |
| Travere Therapeutics, Inc. | 3 | $243 |
| Ardelyx, Inc. | 13 | $217 |
| ANI Pharmaceuticals, Inc. | 10 | $178 |
| Otsuka America Pharmaceutical, Inc. | 5 | $94 |
| Boston Scientific | 1 | $89 |
| Shield Therapeutics Inc | 4 | $71 |
| Novo Nordisk | 3 | $63 |
| Aurinia Pharma U.S., Inc. | 3 | $47 |
| Novartis | 2 | $46 |
| Daiichi Sankyo Inc. | 2 | $32 |
| Apellis Pharmaceuticals, Inc. | 2 | $32 |
| AbbVie | 2 | $29 |
| Abiomed | 1 | $28 |
| Lilly USA, LLC | 1 | $20 |
How this compares
$384,102 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Houston
- Sreedhar MandayamHouston$7M
- Marializa BernardoHouston$4.2M
- Stephen FademHouston$2.4M
- Biruh WorkenehHouston$1.8M
- Rahul PandeyHouston$1.6M
- Christopher KwohHouston$928K
- George NassarHouston$772K
- June YaoHouston$651K
- Maher BisharaHouston$489K
- Wolfgang WinkelmayerHouston$462K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.